Love Me Love My Phages

Copyright © 2005 Elsevier Ltd All rights reserved.

Editorial

Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections

Alexander Sulakvelidze, Vice President, Research & Development, and Chief Scientist, Intralytix, Inc.

Intralytix, Inc., 701 E. Pratt Street, Baltimore, MD 21202, USA

Available online 19 June 2005.

 

 

Drug Discovery Today, Volume 10, Issue 13, 1 July 2005, Page 877

While physicians are increasingly struggling with antibiotic-resistant bacterial infections, the old approach of using bacteriophages to kill antibiotic-resistant bacterial pathogens is not being examined extensively in the Western World

Author Keywords: Bacteriophages; Phage therapy; Drug-resistance; Antibiotic-resistant bacteria

Subject-index terms: Drug Discovery

Article Outline

References

‘…phages are a potentially very valuable tool for dealing with infections caused by antibiotic-resistant bacteria and, in some cases, they might be the only effective modality currently available for saving patients' lives.’

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4GFB8G8-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8a4214d584dcd5c174f89b6b43d4f13c

 The full article will need to be purchased from Elsevier or accessed via University Libraries etc.

Note: Intralytix, Inc is a USA Company that is playing a lead role in research and development of Phage Technology Products. More details later.

............................................................................................................

Copyright © 2007 Elsevier B.V. and the International Society of Chemotherapy All rights reserved.

Review

Bacteriophages: an appraisal of their role in the treatment of bacterial infections

Geoffrey William Hanlon^{, a,}

^aSchool of Pharmacy and Biomolecular Sciences, University of Brighton, Moulsecoomb, Brighton BN2 4GJ, UK

Available online 12 June 2007.

Abstract

Bacteriophages were first used successfully to treat bacterial infections a decade before penicillin was discovered. However, the excitement that greeted those initial successes was short-lived, as a lack of understanding of basic phage biology subsequently led to a catalogue of clinical failures. As a consequence, bacteriophage therapy was largely abandoned in the West in favour of the newly emerging antibiotics. Now, as the problem of antibiotic resistance becomes ever more acute, a number of scientists and clinicians are looking again at bacteriophages as a therapeutic option in the treatment of bacterial infections. The chances of success second time round would appear to be much better given our current extensive knowledge of bacteriophage biology following their important role in underpinning the advances in molecular biology. We also have available to us the experience of nearly 80 years of clinical usage in the countries of the former Soviet Union and Eastern Europe as well as a political climate that encourages sharing of that knowledge. This review outlines those features of bacteriophages that contribute to their utility in therapy and explores the potential for their re-introduction into Western medicine. An abundance of clinical evidence is available in the Soviet literature but much of this is technically flawed and a more realistic appraisal of the clinical value of phages can be obtained from animal studies conducted in the West. As interest in bacteriophages increases, a number of companies throughout the world have begun investing in phage technology and this has led to novel approaches to therapy, some of which will be discussed.

Keywords: Bacteriophages; Phage therapy; Bacterial infections

Article Outline

1. Introduction

2. Bacteriophage biology and interactions with host bacteria

3. Clinical experience of bacteriophages as therapeutic agents

4. Animal studies investigating the potential of phage therapy

5. Bacteriophage preparations

6. Mycovirus

7. Problem therapeutic areas

7.1. Bacteriophage control of biofilm infections

7.2. Mycobacterial infections

8. Novel bacteriophage technologies

8.1. Bacteriophage lysins

8.2. Alteration of the host binding profile

8.3. SASP technology

8.4. Engineered prophages

9. Summary

References

Tel.: +44 1273 642 082.

International Journal of Antimicrobial Agents
Volume 30, Issue 2, August 2007, Pages 118-128

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7H-4NYBMCB-2&_user=10&_origUdi=B6T64-4GFB8G8-1&_fmt=high&_coverDate=08%2F31%2F2007&_rdoc=1&_orig=article&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=b674b6cebb7ad44085ddcbba01c443eb

 

Please note the above link can only be used by copy and paste, and the other links will only work on the original site. Thank You

................................................................................................................................

Copyright © 2003 Elsevier Science Inc. All rights reserved.

Complications: infectious/metabolic

Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man^*1

B. Weber-D browska^a, M. Mulczyk^a and A. Górski^{, , a}

^a L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

Available online 19 June 2003.

 

Article Outline

• References

Corresponding author. Address reprint requests to Andrzej Górski, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 , Wroclaw, , Poland.

*1 Supported by Grant 4PO5B01218 from the KBN. This work is dedicated to the late Prof L. Hirszfeld, founder of the Institute.

Transplantation Proceedings
Volume 35, Issue 4, June 2003, Pages 1385-1386

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VJ0-48W88N9-15&_user=10&_origUdi=B6T64-4GFB8G8-1&_fmt=high&_coverDate=06%2F30%2F2003&_rdoc=1&_orig=article&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=00cee4e08aa016df03a0bfb1cf355889

 

.....................................................................................................................

Copyright © 2008 International Society for Infectious Diseases Published by Elsevier Ltd.

Perspective

Is phage therapy acceptable in the immunocompromised host?

Jan Borysowski^{a, ,} and Andrzej Górski^{a, b}

^aDepartment of Clinical Immunology, Transplantation Institute, The Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland

^bLaboratory of Bacteriophages, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Received 16 October 2007; 

revised 10 December 2007; 

accepted 20 January 2008. 

Corresponding Editor: William Cameron, Ottawa, Canada. 

Available online 8 April 2008.

 

Summary

Over the last decade, bacteriophages (bacterial viruses) have emerged as the major alternative to antibiotics in the treatment of antibiotic-resistant infections. While a considerable body of evidence has accumulated for the efficacy and safety of phage therapy in immunocompetent patients, data remain relatively scarce regarding its use in the immunocompromised host. To our knowledge, the present article is the first to summarize all findings, of both experimental and clinical studies, that may be relevant to the employment of phage therapy in immunocompromised patients. The available data suggest that bacteriophages could also be an efficacious and safe therapeutic modality in such patients.

Keywords: Bacteriophage; Phage therapy; Antibiotic resistance; Immunodeficiency; Immunocompromised host

Article Outline

Introduction

Phage therapy

Phage therapy in the immunocompromised host

Therapeutic efficacy

Safety issues

Immunomodulatory activity of bacteriophages

Conclusions

Acknowledgements

References

Corresponding author. Tel.: +48 22 502 12 62; fax: +48 22 502 21 59.

...........................................................................................................................

               

 

View Within Article

 

 

 

View Within Article

 

 

 

 

 

View Within Article

 

 

 

View Within Article

 

 

 

View Within Article